<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200524047560N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-01-02</date_registration>
      <primary_sponsor>Shahroud University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of propofol intravenous anesthetic and Isoflurane inhalational anesthetic  on QTc interval in ECG of patients receiving methadone maintenance therapy who  are candidate for open limbs surgery.</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of intravenous propofol-remifentanil anesthesia and inhalational  isoflurane-remifentanil anesthesia on QTc interval in patients receiving methadone maintenance therapy who  are candidate for open limbs surgery.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-09-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/48621</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: After informed concern participants, according quadruple  blocks randomization assigns to control or intervention group. Sixty envelope (30 of them with letter A=Intervention and other 30 envelop with letter B= control  based on the randomization table is provided and for each participant corresponding envelope is given to the anesthesiologist by person who is responsible for randomization. Anesthetist, records the group's type in participant's questionnaire and then the envelope is left out, Blinding description: Anesthesiologist and nurse anesthesia are aware of patient's group and this group is recorded in questionnaire by them. Questionnaire has two portion with identical cod. Nurse anesthesia separates data recording portion and gives it to person who is responsible of outcome recording and is unaware of patient grouping. (syringes pump and isoflurane vaporizer have cover.).</study_design>
      <phase>3</phase>
      <hc_freetext>Open reduction and internal fixation of limbs under general anesthesia in methadone maintenance treatment patients..</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: 30 men between the ages of 18 and 60 undergoing maintenance treatment with a minimum dose of 50 mg daily of methadone requiring surgery and under intravenous anesthesia propofol-remifentanil (propofol 100 g / kg / min with remifentanil 1 g / kg / min) And the dose of the drug will be adjusted based on the depth of anesthesia.In this study we use from propofol ( Claris Lifescience limited, India by Daya darou Co.), Isoflurane(Primal critical care inc. USA by Exir Co.) and Remifentanil (GSK by Jahan behbood Co.). Intervention 2: Control group: 30 men between the ages of 18 and 60 undergoing maintenance therapy with a minimum dose of 50 mg daily of methadone who require surgery and will undergo isoflurane-remifentanil inhalation anesthesial (Isoflurane 1.2% with remifentanil 1 microgram /kg/min) and the dose of isoflurane will be adjusted based on the depth of anesthesia.In this study we use from propofol ( Claris Lifescience limited, India by Daya darou Co.), Isoflurane(Primal critical care inc. USA by Exir Co.) and Remifentanil (GSK by Jahan behbood Co.).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is If necessary, a researcher will be provided to them with my coordination.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Javad Nourian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>End of Ayatollah Towheedi Blvd</address>
        <city>Shahroud</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3616911151</zip>
        <telephone>+98 23 3234 2001</telephone>
        <email>javadnourian@gmail.com</email>
        <affiliation>Shahroud University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Javad Nourian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>IH Hospital, End of Ayatollah Towheedi Blvd.</address>
        <city>Shahroud</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>36166-35866</zip>
        <telephone>+98 23 3234 2001</telephone>
        <email>javadnourian@gmail.com</email>
        <affiliation>Shahroud University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Male
Age 18 - 60
Methadone maintenance therapy with a dose of at over 50 mg per day
Open limbs surgery under general anesthesia
Class 1 and 2 of anesthesia risk (According to American society of anesthesiologist's classification)
Normal preoperative heart rate and rhythm</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Male</gender>
      <exclusion_criteria>Use of every drug except methadone in last week
Moderate and severe systemic disorders( anesthesia risk over 2)
Every abnormal heart rate and rhythm
Need for injection of a drug that changes routine anesthesia protocol.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>S52.4</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Fracture of shaft of radius</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: 30 men between the ages of 18 and 60 undergoing maintenance treatment with a minimum dose of 50 mg daily of methadone requiring surgery and under intravenous anesthesia propofol-remifentanil (propofol 100 g / kg / min with remifentanil 1 g / kg / min) And the dose of the drug will be adjusted based on the depth of anesthesia.In this study we use from propofol ( Claris Lifescience limited, India by Daya darou Co.), Isoflurane(Primal critical care inc. USA by Exir Co.) and Remifentanil (GSK by Jahan behbood Co.).</i_keyword>
      <i_keyword>Control group: 30 men between the ages of 18 and 60 undergoing maintenance therapy with a minimum dose of 50 mg daily of methadone who require surgery and will undergo isoflurane-remifentanil inhalation anesthesial (Isoflurane 1.2% with remifentanil 1 microgram /kg/min) and the dose of isoflurane will be adjusted based on the depth of anesthesia.In this study we use from propofol ( Claris Lifescience limited, India by Daya darou Co.), Isoflurane(Primal critical care inc. USA by Exir Co.) and Remifentanil (GSK by Jahan behbood Co.).</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>QT interval. Timepoint: Preoperative - 20 minutes after induction of anesthesia - After recovery. Method of measurement: Record of lead_2 of electrocardiogram.</prim_outcome>
      <prim_outcome>Pulse rate. Timepoint: Preoperative - 20 minutes after induction of anesthesia - After recovery. Method of measurement: Record of lead_2 of electrocardiogram.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Corrected QT. Timepoint: Preoperative- 20 minutes after induction of anesthesia- end of recovery. Method of measurement: QTc calculator software using QT and pulse rate.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahroud University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-11-30</approval_date>
        <contact_name>Ethics Committee of Shahroud University of Medical Sciences</contact_name>
        <contact_address>Shahroud, 7th of Tir Square - Shahroud University of Medical Sciences and Health Services Shahroud Semnan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
